Drug That Helps Improve Walking Speed Approved In US
Main Category: Multiple SclerosisAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 26 Jan 2010 - 0:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
3.9 (10 votes) |
| Healthcare Prof: |  |
3 (1 votes) |
The US Food and Drug Administration (FDA) has approved a drug which has been found to allow people with multiple sclerosis (MS) to walk faster.
People treated with the drug Ampyra (dalfampridine) were found in clinical trials to have faster walking speeds than those treated with a placebo, the American drug watchdog found.
Ampyra, manufactured by Biogen Idec, is the first drug approved by the FDA to help improve walking in people with early forms of MS.
The firm has applied for a license to make the drug available in the UK.
Source
MS Society
Visit our multiple sclerosis section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/177029.php>
APA
http://www.medicalnewstoday.com/releases/177029.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
